Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Patient Perspectives on Electronic Communication of Cancer Diagnoses.

JAMA network open·2026
Same author

Predictive Biomarkers for Immune Checkpoint Inhibitor Efficacy: Challenges, Innovations, and a Pathway to Precision Medicine in the Era of Cancer Immunotherapy.

Clinical chemistry·2026
Same author

Deciphering small sequence differences in T cell receptor-antigen pairing.

Nature communications·2026
Same author

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial.

JAMA·2026

Related Experiment Video

Updated: Jun 23, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K

Immune Checkpoint Inhibitor Outcomes in NSCLC Across Populations and Practice Settings.

Matthew Lee1, Jialing Liu2, Kari J Teigen3

  • 1UT Southwestern Medical School, University of Texas Southwestern Medical Center, Dallas, Texas.

JTO Clinical and Research Reports
|March 19, 2026
PubMed
Summary

Immune checkpoint inhibitors (ICI) improved survival for advanced NSCLC patients in safety-net settings, regardless of race or socioeconomic status. Expanding ICI access can enhance outcomes for diverse patient populations.

Keywords:
ICINon–small cell lung cancerReal-worldSafety-net

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

6.0K

Related Experiment Videos

Last Updated: Jun 23, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

6.0K

Area of Science:

  • Oncology
  • Immunotherapy
  • Health Disparities

Background:

  • Immune checkpoint inhibitor (ICI) clinical trials predominantly enroll non-Hispanic White patients in academic or private settings.
  • Limited data exists on ICI outcomes in safety-net healthcare systems and diverse patient populations.

Purpose of the Study:

  • To evaluate the effectiveness of ICI in a diverse patient cohort within a safety-net healthcare system compared to an academic cancer center.
  • To assess survival outcomes associated with ICI treatment across different practice settings, races, ethnicities, and socioeconomic statuses.

Main Methods:

  • Retrospective study of 408 patients with advanced non-small cell lung cancer (NSCLC).
  • Data collected from electronic medical records in safety-net and academic settings.
  • Kaplan-Meier estimates and Cox proportional hazards models used for survival analysis.

Main Results:

  • The safety-net cohort was younger, more racially/ethnically diverse, and had lower socioeconomic status compared to the academic cohort.
  • Patients receiving ICI (alone or with chemotherapy) demonstrated significantly improved survival compared to chemotherapy alone (aHRs ranging from 0.44 to 0.54).
  • No significant differences in survival were observed based on race, ethnicity, or socioeconomic status.

Conclusions:

  • ICI treatment is associated with improved survival in a diverse patient population across different healthcare settings.
  • The benefits of ICI appear consistent regardless of facility type, race, ethnicity, or socioeconomic status.
  • Efforts to broaden access to ICI for all eligible patients are crucial for improving oncological outcomes.